Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184 in Adults With Human Immunodeficiency Virus (HIV)

The study objective was to evaluate the absolute oral bioavailability of [14C]VH4524184 and its mass balance in participants with human immunodeficiency virus (HIV). This assessment is clinically relevant for characterizing systemic exposure and the extent of recovery of the administered dose. No secondary objectives were specified.

The sponsor did not provide information on the total number of participants. The study population included healthy volunteers of both sexes, with an age range corresponding to code 3. No additional details were provided regarding selection of the trial population, lifestyle considerations, or relevant inclusion or exclusion criteria. The trial involved participants in relation to human immunodeficiency virus (HIV).

The trial is a phase 3 study of human immunodeficiency virus (HIV). The available source data do not describe the detailed trial design, randomization, blinding, control procedures, or the sequence and purpose of study visits. The estimated trial period is from 2026-06-04 to 2026-08-20. No information is provided on the expected length of participant involvement, follow-up visits, end-of-study procedures, or conditions for early termination from the study.

No investigational or comparator treatments were specified in the source data. No pharmaceutical form, dosage, route, frequency of administration, dosing schedule, or compliance monitoring information was provided.

Efficacy will be assessed in the clinical trial for human immunodeficiency virus (HIV).